Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 795

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 795
---
 | 43.12 |

The following table summarizes the Company’s outstanding common stock warrants as of December 31, 2023:

| Description of warrants      
 2022 April Investor warrants 
 2022 Investor warrants       |     | Number         
 (in thousands) | 325 
 240 |     | Exercise 
 price $  |           20.50 
           62.50 |     | Expiry date | April 14, 2027                       
 March 28, 2025                       |
|:-----------------------------|:----|:---------------|----:|:----|:---------|----------------:|:----|:------------|:-------------------------------------|
| 2020 Investor warrants       |     |                |  65 |     |          |           50.00 |     |             | August 16, 2024                      |
| 2019 Investor warrants       |     |                |  15 |     |          |          155.00 |     |             | June 5, 2024                         |
| NBTS Warrants                |     |                |   3 |     |          |           54.50 |     |             | June 19, 2025                        |
| Warrants issued for services |     |                |   7 |     |          | 32.00 to 137.50 |     |             | January 7, 2024 to February 25, 2024 |
| 2022 April Agent warrants    |     |                |  32 |     |          |           33.12 |     |             | October 14, 2026                     |
| 2022 Agent warrants          |     |                |  12 |     |          |           78.12 |     |             | March 28, 2025                       |
| 2019 Agent warrants          |     |                |   1 |     |          |          193.75 |     |             | June 3, 2024                         |
|                              |     |                | 700 |     |          |                 |     |             |                                      |

F-63

Kintara Therapeutics, Inc. Notes to Condensed Consolidated Interim Financial Statements (Unaudited) December 31, 2023 (expressed in US dollars and in thousands, except par value and per share amounts, unless otherwise noted) Series C Preferred Stock warrants In connection with the Series C Preferred Stock private